×

Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors

SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that Renee Tannenbaum, Pharm.D., has been appointed as a new member of the Company's Board of Directors.

Cam L. Garner, Chairman of the Board, said, "Dr. Tannenbaum has significant experience developing and executing commercial strategies in the pharmaceutical industry. Her strong track record of success covers a range of relevant areas including product launches, sales and marketing, product development, alliance management, commercial strategies, and leadership development. We look forward to drawing on her considerable experience as the Company continues to execute on its commercial and new product initiatives."

Dr. Tannenbaum currently serves as the Head of Global Customer Excellence of AbbVie, Inc., where she is responsible for building commercial capabilities for the organization. Prior to joining AbbVie, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm. From 2009 to 2011, she served as Executive Vice President and Chief Commercial Officer at Elan Pharmaceutics, Inc., where she was responsible for revenue generation for Elan's marketed products, preparing for the commercialization of the company's pipeline, including its Alzheimer's portfolio, and strengthening the company's overall commercial capabilities.

Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, she spent nine years at Bristol Myers Squibb and 16 years at Merck and Company where she held a variety of leadership positions in operations and general management.

Prior to joining the industry, Dr. Tannenbaum was an Assistant Professor of Clinical Pharmacy at the Philadelphia College of Pharmacy and Sciences, now known as the University of the Sciences at Philadelphia. She retains a faculty position at the University's Mayes College of Healthcare Business and Policy and serves as the Dean's Professor.

Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut. She currently serves on the advisory board of the Women Business Leaders in U.S. Healthcare Industry Foundation and the advisory board for the Healthcare Businesswomen's Association.

Dr. Tannenbaum commented, "I am pleased to join the Zogenix Board of Directors and to have the opportunity to help refine the Company's strategic growth initiatives and contribute to the advancement and potential commercialization of ZX008 and Relday. The Company has an attractive mix of commercial and pipeline potential in large markets. I look forward to working closely with the Board and management as the Company moves forward toward several key potential milestones in the next few years."

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning.

Forward Looking Statements

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the potential commercialization of ZX008 and Relday and the achievement of key development and regulatory milestones. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Zogenix's business, including, without limitation: difficulties or delays relating to the development, testing, manufacturing and marketing of and obtaining regulatory approval for Zogenix's product candidates; Zogenix's dependence on third parties to develop its product candidates; and other risks detailed in Zogenix's prior press releases as well as in public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FPR

CONTACT: Investors Zack Kubow, The Ruth Group 646.536.7020, zkubow@theruthgroup.comSource:Zogenix